**TOPICAL REVIEW**

**PITX2-dependent gene regulation in atrial fibrillation and rhythm control**

Fahima Syeda¹, Paulus Kirchhof¹,²,³ and Larissa Fabritz¹,²,⁴

¹Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK
²Department of Cardiology, UHB NHS Trust, Birmingham, UK
³Department of Cardiology, SWBT, Birmingham, UK
⁴Department of Cardiovascular Medicine, Division of Rhythmology, University Hospital Münster, Münster, Germany

**Abstract** Atrial fibrillation (AF) is a common arrhythmia. Better prevention and treatment of AF are needed to reduce AF-associated morbidity and mortality. There are several major mechanisms that cause AF in patients, including a genetic predisposition to develop AF. Genome-wide association studies have identified genetic variants associated with AF populations, with the strongest hits clustering on chromosome 4q25, close to the gene for the homeobox transcription factor PITX2. PITX2 regulates several key aspects of cardiac physiology, including L-type calcium channels, voltage-gated potassium channels, and IK channels. These alterations contribute to the development of atrial fibrillation and other arrhythmias. This review provides an overview of the role of PITX2 in the pathogenesis of atrial fibrillation and potential targets for therapeutic intervention.
Atrial fibrillation (AF) affects 2–3% of the population in Europe and the US and the prevalence of AF is rising (Schnabel et al. 2015; Kirchhof et al. 2016). AF is a significant cause of death, stroke, dementia and reduced quality of life in the Western world and this issue is complicated by a lack of effective therapies. The treatment of AF has four different domains: treatment of underlying cardiovascular conditions, stroke prevention, rate control and rhythm control. Even on optimal stroke prevention and rate control therapy, cardiovascular morbidity and mortality remains high (Marijon et al. 2013; Bassand et al. 2016). The success of rhythm control therapy is often unpredictable and recurrence is common. This outcome is partly attributable to our limited understanding of the underlying genetic causes of AF and the interaction of these causes with type of rhythm control therapy. Initial observations suggest that the haplotype of common AF-related variants modifies the outcome of anti-arrhythmic therapy (Parvez et al. 2012; Huang & Darbar, 2016), suggesting that rhythm control therapy could benefit from precision and personalisation based on genomomic information.

AF has a heritable component

AF appears to be familial in approximately 15% of early-onset AF without concomitant diseases and 5% of all AF cases (Darbar et al. 2003), and a family history of early-onset AF increases overall AF risk (Fox et al. 2004). Linkage and functional studies have revealed the mutation of several potassium channels such as KCNQ1, KCNE2, KCNH2 in rare, monogenic families with a Mendelian pattern of AF inheritance (Chen et al. 2003; Yang et al. 2004; Hong et al. 2005; Xia et al. 2005). These gain or loss of function potassium channel mutations may account for some of the electrophysiological changes that promote AF, such as reduced wavelength or early after-depolarisations, respectively. However, most AF patients do not harbour these rare genotypes with clear phenotypes, so the polygenic and multifactorial nature of AF is an important avenue of research. Therefore, transcriptional regulators with multiple effectors may play a significant role in familial AF caused by common genetic variants.

Common gene variants associated with AF

Genome-wide association studies (GWAS), unbiased correlation studies designed to identify associations between allele frequencies and trait variation, have identified multiple loci that associate with AF (Gudbjartsson et al. 2007; Benjamin et al. 2009; Kaab et al. 2009; Ellinor et al. 2010, 2012; Schnabel et al. 2011). Initial GWAS identified two single nucleotide polymorphisms (SNPs; rs2200733 and rs10033464) in European and Chinese populations (Gudbjartsson et al. 2007) on chromosome 4q25. Other loci exist on chromosome 16q22 within intron 1 of the gene encoding ZHFX3, i.e. zinc finger homeobox protein 3 (Benjamin et al. 2009) and on chromosome 1q21 on intron 1 of the gene for KCNN3 (involved in calcium-activated potassium channels; Ellinor et al. 2010). Since these initial studies, a multitude of SNPs that associate with AF have been...
identified on chromosome 4q25. The gene variants on chromosome 4q25 are intergenic, but many of them are in a genomic ‘desert’ approximately 150 kb upstream from the gene for PITX2 (paired-like homeodomain transcription factor).

**The PITX gene family**

The PITX family of homeobox transcription factors consists of PITX1, PITX2 and PITX3, each of which has distinct and overlapping expression patterns, therefore functions, in different organs (Cox et al. 2002). All three members of the PITX family, but predominantly PITX2 and PITX3, are expressed in the anterior segment of the eye. In humans, PITX2 mutations are associated with Axenfeld-Rieger syndrome and PITX3 mutations with congenital cataracts (Semina et al. 1998). PITX1 is also essential for hindlimb and pituitary development (Szeto et al. 1999), and PITX2 for tooth, heart, lung and abdominal development in the mouse (Lin et al. 1999).

Three PITX2 isoforms (PITX2a, PITX2b and PITX2c), which are generated by alternative splicing and differential promoter usage of the PITX2 gene, are highly expressed in mice and humans during development (Schweickert et al. 2000). The PITX2d isoform, which exists in humans only, suppresses the transcriptional activity of the PITX2a and PITX2c isoforms (Cox et al. 2002). The predominant cardiac isoform of PITX2 is PITX2c (Kirchhof et al. 2011).

**PITX2 promotes left–right asymmetry**

PITX2 was initially described in the context of embryonic development of left–right asymmetry of internal organs: it is expressed in the left heart and gut of the mouse, chick and *Xenopus*, and its misexpression alters position and the twisting of organs (Ryan et al. 1998; Lin et al. 1999; Campione et al. 2001).

The cardiac system shows left–right asymmetry, e.g. normal coordinated heartbeat is generated from the sinoatrial nodal pacemaker cells in the right atrium. The development of cardiac left–right specific characteristics such as the restriction of the sinoatrial node to the right atrium is critically dependent on asymmetrical organ morphogenesis (Mommestaeg et al. 2007; Galli et al. 2008). Cardiac left–right asymmetry is subject to left-sided PITX2 expression (Galli et al. 2008; Tessari et al. 2008), particularly the PITX2c isoform (Schweickert et al. 2000; Kirchhof et al. 2011) through the left–nodal programming pathway (Wang et al. 2010).

**PITX2-dependent gene expression in the adult heart**

Triggered by the GWAS study pointing to a possible role for PITX2 in AF, the role of PITX2 in the adult heart, in addition to its role in left–right asymmetry and cardiac development, has been investigated: Pitx2c expression continues in the postnatal left atrium in mice and humans (Wang et al. 2010; Kahr et al. 2011; Kirchhof et al. 2011) and there is progressive loss of Pitx2c with age in mice (Wang et al. 2010). Thus, Pitx2c dysregulation has the potential to influence AF in adulthood and senescence.

In AF, fast irregular atrial beats overtake the sinoatrial node, sometimes also resulting in ventricular arrhythmias. The origins of ectopic electrical activity are often in the pulmonary veins (Haisaguerre et al. 1998; Po et al. 2005) and if from the left atrium, then predominantly from the left atrial posterior wall (Sanders et al. 2005; Holmes et al. 2016). Given the crucial role of PITX2 in left–right asymmetry, it is probable that loss of PITX2 in some cases of heritable AF causes incomplete suppression of pacemaker activity in the left heart. This has been shown to be mediated by the loss of Shox2-silencing and increase in *Hcn4* (Wang et al. 2010).

**PITX2 mRNA concentrations regulate atrial function**

Both under- and overexpression of PITX2 has been found to be associated with AF (Chinchilla et al. 2011; Perez-Hernandez et al. 2016) in humans. The variability of PITX2 in AF patients suggests that there is a critical level of PITX2 for normal atrial function in the adult. We have recently shown a PITX2 mRNA gradient in AF patients requiring AF ablation. Hence, AF patients could be categorised according to PITX2 levels (Syeda et al. 2016). The mechanisms of AF promotion are diverse, and there are multiple pathways by which PITX2 could regulate arrhythmogenesis. This is unsurprising given that PITX2 is a transcription factor with multiple targets (Hjalt & Semina, 2005). Reduced Pitx2 expression was associated with higher susceptibility to inducible atrial arrhythmias including AF in mice as observed by several groups (Wang et al. 2010; Chinchilla et al. 2011; Kirchhof et al. 2011). Shortened atrial action potential durations, a phenomenon facilitating re-entry, were associated with Pitx2 deficiency (Kirchhof et al. 2011).

Postnatal conditional deletion of all Pitx2 isoforms in the left atrium (Pitx2 CKO; achieved by using the muscle creatine kinase-Cre driver) generally resulted in upregulation of genes signifying that, on the whole, PITX2 represses translation. The Pitx2 CKO mouse had irregular resting heart rates and low amplitude P waves (Tao et al. 2014). The upregulation of genes associated with structural remodelling (e.g. integrin α 3 and 5) and cell-junction assembly (e.g. desmoplakin and connexin43) indicates that loss of Pitx2 may cause structural remodelling and damage to the intercalated disc (Tao et al. 2014). Prenatal atrial-specific deletion of all Pitx2 isoforms achieved by using a Nppa-Cre driver (*NppaCre* Pitx2<sup>−/−</sup>) results in modest atrial enlargement and wall thinning during embryonic development.
Heterozygous deletion of isoform c-specific exon 4 resulting in a 40% reduced left atrial Pitx2c expression (Pitx2c<sup>c+/−</sup>), in contrast, did not cause any obvious structural abnormalities (Kirchhof et al. 2011).

Pitx2 overexpression can promote repair after myocardial injury. So it appears that there is a dynamic Pitx2 response to stress and metabolic changes (Tao et al. 2016). Cis-regulatory elements for the transcription factor Tbx5 in regions analogous to the human PITX2 risk locus have also been found in the mouse. Postnatal deletion of Tbx5 led to Pitx2 reduction and caused atrial arrhythmias by action potential duration prolongation (Nadadur et al. 2016). Interestingly, an inverse relationship between the effects of Tbx5 on some AF-relevant ion channel expression and the effects of Pitx2 on the same ion channels was observed (Tao et al. 2014) and the loss of Pitx2 reversed the pro-arrhythmic effects of the loss of Tbx5 because the loss of either facilitated AF through opposite mechanisms (Nadadur et al. 2016).

Based on several animal models of Pitx2 loss, where haploinsufficiency of Pitx2 has resulted in a less severe phenotype than complete deletion, it can be deduced that there is a dose-dependent regulation of atrial function by Pitx2 in the adult left atrium (Wang et al. 2010; Kirchhof et al. 2011; Lozano-Velasco et al. 2016).

**PITX2-dependent ion channel regulation**

Several potassium channel (Wang et al. 2010; Chinchilla et al. 2011; Kirchhof et al. 2011; Syeda et al. 2016) and calcium handling genes (Tao et al. 2014; Lozano-Velasco et al. 2016) are regulated by Pitx2, as seen in mutant Pitx2 models (see Abstract figure). The action potential duration shortening observed in Pitx2c<sup>+/−</sup> mice (Kirchhof et al. 2011) and depolarised resting membrane potential in NppaCre<sup>+/−</sup> mice and Pitx2c<sup>+/−</sup> mice suggests that Pitx2 regulates the expression of several potassium channels contributing to atrial repolarisation and to the resting membrane potential. Indeed, in NppaCre<sup>−/−</sup>Pitx2<sup>−/−</sup> mice, expression of Kcnj2 is decreased (Chinchilla et al. 2011), which would cause a decrease in inward rectifier potassium ion channel (I<sub>K1</sub>), the primary determinant of the resting membrane potential. In Pitx2c<sup>+/−</sup> mice, both the expression of TWIK-related acid-sensitive K<sup>+</sup> channel (TASK-2) and TASK-like background currents, contributors to the resting membrane potential, were reduced, though I<sub>K1</sub> was not altered (Syeda et al. 2016).

**Non-protein targets of PITX2**

Multiple microRNAs (miRNAs), short non-coding strands of RNA that usually induce post-transcriptional gene-silencing and fine-tune gene signalling during tissue development and homeostatic control (Beermann et al. 2016), are downstream from Pitx2 and involved in AF pathogenesis. Pitx2 expression co-localises with miR-17-92 cluster expression, and loss of Pitx2 results in loss of multiple miRNAs that are encoded by miR-17-92 and its closely related homologue miR-106b-25. Mice deficient in these miRNA clusters share similar characteristics to Pitx2-deficient mice including induced arrhythmia susceptibility and dysregulation of Shox2 and Tbx3 (Wang et al. 2014). The multiple miRNAs regulated by Pitx2 may partly explain how Pitx2 modulates several pathways potentially leading to AF (Li et al. 2016).

**Interactions between SNPs and transcription factors**

Several genes that are either associated with AF in patients who have common intronic or distal variants shown by GWAS or rare variants that directly cause AF as shown by linkage analysis, interact with PITX2. These include genes for Tbx5 (Huang et al. 2015; Ma et al. 2016; Nadadur et al. 2016), HCN4 (Wang et al. 2010; Mahida & Ellinor, 2012), KCNN3 (Ellinor et al. 2010; Mahida & Ellinor, 2012; Lozano-Velasco et al. 2016), KCNJ2 (Xia et al. 2005; Chinchilla et al. 2011), CAV-1 (Mahida & Ellinor, 2012; Lozano-Velasco et al. 2016) and ZFHX3 (Chen et al. 2003; Wang et al. 2010), as seen in murine models. Thus, PITX2 potentially regulates AF through several genes already implicated in AF.

It has also been observed that SNPs on different AF susceptibility loci (e.g. rs2200733 on chromosome 4q25 and rs2106261 on chromosome 16q22) interact with each other in AF (Huang et al. 2015) and Zfkh3 has been identified as a possible target for Pitx2 through CHIP-Seq analysis (Tao et al. 2014). Furthermore, the expression of Pitx2c mRNA positively correlates with ZFHX3 mRNA expression through miR-1 (Huang et al. 2015).

Chromosome conformation capture studies have shown that there is long-range interaction between the risk locus at 4q25 and the PITX2c promoter (Aguirre et al. 2015), but beyond this finding, there is little information on how variants distal to PITX2 interact with PITX2 to cause AF. Interestingly, an AF-associated SNP proximal to PITX2 has been shown to regulate PITX2c expression in human stem cell-derived cardiomyocytes by regulating PITX2 enhancer activity (Ye et al. 2016).

Though the interaction between genetic variants close to PITX2 and PITX2 itself is not completely understood, the effects of the loss of PITX2 appear to converge with the presence of AF-associated SNPs.

**The potential to use PITX2 to personalise AF therapy**

Clinical observational studies have suggested that common AF risk alleles at chromosome 4q25 near PITX2 modify response to anti-arrhythmic therapy in patients (Parvez et al. 2012). Low Pitx2 mRNA also improved the effectiveness of sodium channel blockers in a prospective

© 2017 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
experimental study (Syeda et al. 2016). PITX2 levels vary in AF patients (Syeda et al. 2016) and given the observation that loss of left atrial Pitx2 facilitates AF, it may be desirable to target those AF patients who have low PITX2 as a distinct population for therapy. There is, however, no clear relation between atrial tissue PITX2 mRNA levels and SNP haplotype of the common gene variants associated with AF in patients (Gore-Panter et al. 2014, 2016; Syeda et al. 2016).

The current limited success of rhythm control therapy is thought to be due to heterogeneous drivers causing recurrent AF and modulating treatment response (Fabritz et al. 2016). Amongst the plethora of putative downstream targets of Pitx2, the resting membrane potential (Chinchilla et al. 2011; Syeda et al. 2016) is one that has been seen to be a good predictor of the sodium channel blocking effects of flecainide in isolated cells of human and mouse origin (Syeda et al. 2016). The resting membrane potential is also a good predictor of flecainide’s anti-arrhythmic effectiveness. By using a more precisely targeted approach, these observations of PITX2-dependent effects may help improve rhythm therapy in the future.

### Open questions regarding research into PITX2

1. A robust method for identification of patients with high and low atrial PITX2 levels is needed. Clearly, measuring PITX2 expression in atrial tissue of people who are not candidates for surgery is impracticable, so surrogate blood biomarkers of PITX2 could be used to subtype AF patient populations to bring about much-needed leaps in personalised predictions of both AF risk and response to therapy. Currently, the P wave in the ECG still remains the best biomarker for AF (Fabritz, 2016).

2. Well-designed clinical trials to assess the PITX2 dependence of the effectiveness of rhythm control therapy could help to re-evaluate anti-arrhythmic drugs that have often been ineffective thus far. It is likely that these findings are not limited to PITX2 and the assessment of genotype dependence on the effectiveness of other anti-arrhythmic drugs could be approached in this manner.

3. Further exploration of the relevance of the resting membrane potential for anti-arrhythmic drug therapy success in patients could be valuable.

4. Determination of the major clinical types of AF reflecting different drivers of the arrhythmia, e.g. ‘early onset AF’ as a proxy for genetic predisposition to AF.

5. Characterisation of the interaction of atrial stressors that are often concurrent with AF, with different PITX2 expression levels could also guide the choice of anti-arrhythmic drug.

### Conclusions

Although the entire scope of the activities and interactions of PITX2 are yet to be elucidated, it is clear that PITX2 has important functions in the adult left atrium and there is evidence in animal models that reduced Pitx2 mRNA levels predispose atria to AF by changing its electrical function, whether by abnormal pacemaker activity or adverse electrical remodelling. While complete deletion of Pitx2 results in structural abnormalities, moderate reduction in atrial Pitx2 levels primarily alters electrical function of the atria, for example the resting membrane potential and ion channel function.

Apparently, AF-associated SNPs on chromosome 4q25 in close proximity to the PITX2 gene do not directly relate to atrial PITX2 mRNA concentrations. Nonetheless, given emerging evidence that PITX2 not only contributes to AF but could be used to predict effectiveness of rhythm control therapy, further investigations into the key co-factors, regulators and targets of PITX2 could change the current strategies used to determine the choice of anti-arrhythmic drugs.

Pitx2 alters the atrial resting membrane potential and thereby modulates the effectiveness of sodium channel blockers in mice. Reliable methods to identify alterations in PITX2 expression in humans may help to make an informed choice on anti-arrhythmic drug therapy.

### References


is mutated in 7000.0000099534.


Additional information

Competing interests

L. Fabritz has received institutional research grant support from Deutsche Forschungsgemeinschaft, Medical Research Council, British Heart Foundation and Gilead Inc. P. Kirchhof has received research support from the German Centre for Heart Research, from several drug and device companies active in atrial fibrillation, and has received honoraria from several such companies. F. Syeda, L. Fabritz and P. Kirchhof are listed as inventors on a patent (WO2015/140571) held by the University of Birmingham on genotype-specific anti-arrhythmic drug therapy of atrial fibrillation.

Funding

This work was supported by the European Union (grant agreement No. 633196 (CATCH ME) to P.K. and L.F.), the British Heart Foundation (FS/13/43/30324 to P.K. and L.F.) and the Leducq Foundation to P.K.